It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Accumulating evidence points to dysregulations of the Nucleus Accumbens (NAc) in eating disorders (ED), however its precise contribution to ED symptomatic dimensions remains unclear. Using chemogenetic manipulations in male mice, we found that activity of dopamine D1 receptor-expressing neurons of the NAc core subregion facilitated effort for a food reward as well as voluntary exercise, but decreased food intake, while D2-expressing neurons have opposite effects. These effects are congruent with D2-neurons being more active than D1-neurons during feeding while it is the opposite during running. Chronic manipulations of each subpopulations had limited effects on energy balance. However, repeated activation of D1-neurons combined with inhibition of D2-neurons biased behavior toward activity-related energy expenditure, whilst the opposite manipulations favored energy intake. Strikingly, concomitant activation of D1-neurons and inhibition of D2-neurons precipitated weight loss in anorexia models. These results suggest that dysregulations of NAc dopaminoceptive neurons might be at the core of EDs.
Increasing evidence point to a dysfunction of the nucleus accumbens (NAc) in eating disorders. Here, the authors provide evidence that dysregulation of the activity of NAc dopaminoceptive neuronal subpopulations is sufficient to alter energy balance.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 NutriNeuro, Université de Bordeaux, INRAE, Bordeaux INP, Bordeaux, France (GRID:grid.488493.a) (ISNI:0000 0004 0383 684X)
2 UMR5293 F-33000, Univ. Bordeaux, CNRS, IMN, Bordeaux, France (GRID:grid.412041.2) (ISNI:0000 0001 2106 639X)
3 ULB Neuroscience Institute, WELBIO, Université Libre de Bruxelles (ULB), Laboratory of Neurophysiology, Brussels, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 6355)
4 NutriNeuro, Université de Bordeaux, INRAE, Bordeaux INP, Bordeaux, France (GRID:grid.488493.a) (ISNI:0000 0004 0383 684X); F-, Bordeaux Sciences Agro, Gradignan, France (GRID:grid.434203.2) (ISNI:0000 0001 0659 4135)
5 University Medical Center Utrecht, Universiteitsweg 100, Department of Translational Neuroscience, UMC Utrecht Brain Center, Utrecht, Netherlands (GRID:grid.7692.a) (ISNI:0000 0000 9012 6352); Altrecht Eating Disorders Rintveld, Zeist, the Netherlands (GRID:grid.7692.a)
6 Douglas Hospital, McGill University, Department of Psychiatry, Montreal, Canada (GRID:grid.412078.8) (ISNI:0000 0001 2353 5268); CNRS; F-75006, Université de Paris Cité, INCC UMR 8002, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602)
7 NeuroCentre INSERM U1215, Endocannabinoids and NeuroAdaptation, Bordeaux, France (GRID:grid.508487.6); Université de Bordeaux, Bordeaux, France (GRID:grid.412041.2) (ISNI:0000 0001 2106 639X)